These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26837238)

  • 1. Effects of Combined Milrinone and Levosimendan Treatment on Systolic and Diastolic Function During Postischemic Myocardial Dysfunction in a Porcine Model.
    Axelsson B; Häggmark S; Svenmarker S; Johansson G; Gupta A; Tydén H; Wouters P; Haney M
    J Cardiovasc Pharmacol Ther; 2016 Sep; 21(5):495-503. PubMed ID: 26837238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency.
    Pagel PS; Hettrick DA; Warltier DC
    Basic Res Cardiol; 1996; 91(4):296-307. PubMed ID: 8874779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
    Hillestad V; Kramer F; Golz S; Knorr A; Andersson KB; Christensen G
    J Appl Physiol (1985); 2013 Nov; 115(10):1572-80. PubMed ID: 24072410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
    Pagel PS; Harkin CP; Hettrick DA; Warltier DC
    Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
    Harkin CP; Pagel PS; Tessmer JP; Warltier DC
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Milrinone and levosimendan during porcine myocardial ischemia -- no effects on calcium overload and metabolism.
    Axelsson B; Johansson G; Abrahamsson P; Gupta A; Tydén H; Wouters P; Haney M
    Acta Anaesthesiol Scand; 2013 Jul; 57(6):719-28. PubMed ID: 23517167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
    Stocker CF; Shekerdemian LS; Nørgaard MA; Brizard CP; Mynard JP; Horton SB; Penny DJ
    Crit Care Med; 2007 Jan; 35(1):252-9. PubMed ID: 17133188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.
    Sonntag S; Sundberg S; Lehtonen LA; Kleber FX
    J Am Coll Cardiol; 2004 Jun; 43(12):2177-82. PubMed ID: 15193677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
    Banfor PN; Preusser LC; Campbell TJ; Marsh KC; Polakowski JS; Reinhart GA; Cox BF; Fryer RM
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H238-48. PubMed ID: 17982006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of milrinone before ischemia, in the presence of beta-blockade, to treat metabolic impairment and myocardial stunning in pigs.
    Sidi A; Muehlschlegel JD; Kirby DS; Lobato EB
    Acta Anaesthesiol Scand; 2008 Mar; 52(3):397-405. PubMed ID: 18269389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
    Kolseth SM; Wahba A; Kirkeby-Garstad I; Aro S; Nordgaard H; Høydal M; Rognmo Ø; Nordhaug D
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):1377-83. PubMed ID: 22219475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy.
    Pagel PS; McGough MF; Hettrick DA; Lowe D; Tessmer JP; Jamali IN; Warltier DC
    J Cardiovasc Pharmacol; 1997 May; 29(5):563-73. PubMed ID: 9213196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts.
    Kristof E; Szigeti G; Papp Z; Bodi A; Ball NA; Walsh RA; Edes I
    Basic Res Cardiol; 1999 Aug; 94(4):223-30. PubMed ID: 10505421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction.
    Missant C; Rex S; Segers P; Wouters PF
    Crit Care Med; 2007 Mar; 35(3):707-15. PubMed ID: 17255859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.
    Rump AF; Acar D; Klaus W
    Br J Pharmacol; 1994 Jul; 112(3):757-62. PubMed ID: 7921599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
    Givertz MM; Andreou C; Conrad CH; Colucci WS
    Circulation; 2007 Mar; 115(10):1218-24. PubMed ID: 17339544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs.
    Sidi A; Muehlschlegel JD; Kirby DS; Lobato EB
    Ann Card Anaesth; 2007 Jan; 10(1):34-41. PubMed ID: 17455406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine.
    Shibata I; Cho S; Yoshitomi O; Ureshino H; Maekawa T; Hara T; Sumikawa K
    Scand Cardiovasc J Suppl; 2013 Feb; 47(1):50-7. PubMed ID: 22994851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.